These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
565 related articles for article (PubMed ID: 33683644)
1. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study. Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644 [TBL] [Abstract][Full Text] [Related]
2. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Bekaii-Saab TS; Bridgewater J; Normanno N Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504 [TBL] [Abstract][Full Text] [Related]
3. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? Aitcheson G; Mahipal A; John BV Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096 [No Abstract] [Full Text] [Related]
4. Systemic treatment of advanced or recurrent biliary tract cancer. Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166 [TBL] [Abstract][Full Text] [Related]
5. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Chong DQ; Zhu AX Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study. Vancanneyt J; Wilmsen B; Luyten C; Verslype C; Van Cutsem E; Roskams T; Tejpar S; Vanden Bempt I; Dekervel J J Cancer Res Clin Oncol; 2023 Sep; 149(11):9173-9181. PubMed ID: 37184679 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive molecular profiling broadens treatment options for breast cancer patients. Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848 [TBL] [Abstract][Full Text] [Related]
10. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. Lee H; Wang K; Johnson A; Jones DM; Ali SM; Elvin JA; Yelensky R; Lipson D; Miller VA; Stephens PJ; Javle M; Ross JS J Clin Pathol; 2016 May; 69(5):403-8. PubMed ID: 26500333 [TBL] [Abstract][Full Text] [Related]
12. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382 [TBL] [Abstract][Full Text] [Related]
13. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042 [TBL] [Abstract][Full Text] [Related]
14. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. King G; Javle M Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489 [TBL] [Abstract][Full Text] [Related]